The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Open accessAbstract
Purpose: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy. Patients and Methods: We identified 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007. Patients were compared by groups: 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondiabetic patients. pCR rates were compared between the three groups using χ 2 tests of independence and compared pair- wise using a binomial test of proportions. Factors predictive of pCR were assessed using a multivariate logistic regression model. Results: The rate of pCR was 24% in the metformin group, 8.0% in the nonmetformin group, and 16% in the nondiabetic group (P = .02). Pairwise comparisons between the metformin and nonmetformin groups (P = .007) and the nonmetformin and nondiabetic groups (P = .04) were significant. Comparison of the pCR rates between the metformin and nondiabetic groups trended toward but did not meet significance (P = .10). Metformin use was independently predictive of pCR (odds ratio, 2.95; P = .04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Conclusion: Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin. Additional studies to evaluate the potential of metformin as an antitumor agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin has also been found to cooperate with neo-adjuvant chemotherapy to result in complete tumor regression in some breast cancer patients (Jiralerspong et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Jiralerspong et al., 2009
In the citing paper
“Type 2 diabetic patients receiving neo-adjuvant chemotherapy for breast cancer as well as metformin were more likely to have pathologic complete response (pCR) than patients not receiving it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“However, despite the increase in pCR, metformin did not significantly improve the estimated 3-year relapse-free survival rate [156].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“There is further evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270), and there are now more than 100 ongoing trials”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“Metformin treatment was associated with higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy (95).”
From Diabetes and Cancer (2010) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Insulin-like growth factors and neoplasia
Pollak, M., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1387 · Cited by 1,477
Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Research works printed but not linked: 3
- Mieog JS, 2007, Cochrane Database Syst Rev, 2, CD005002
- 10.1200/JCO.2002.20.1.42 · DOI
- Fairey AS, 2003, Cancer Epidemiol Biomarkers Prev, 12, 721
Cited by
Sorted by citations
Items 401–500 of 879
Obesity and Cancer: Overview of Mechanisms
Nock, N. L., & Berger, N. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5515-9_5 · Cited by 35
Li, H., Chen, X., Yu, Y., Wang, Z., Zuo, Y., Li, S., Yang, D., HU, S., XIANG, M., Xu, Z., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3485 · Cited by 35
Hakimi, A. A., Chen, L., Kim, P. H., Sjoberg, D. D., Glickman, L., Walker, M. R., & Russo, P. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.1447 · Cited by 37
Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges
Yung, M. M. H., Ngan, H., & Chan, D. W. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv128 · Cited by 35
“For instance, diabetic patients with breast cancer who had already taken metformin apparently showed a better response to chemotherapy than nondiabetics and diabetics without metformin treatment [135].”
BackgroundJiang, S., Wang, Y., Luo, L., Shi, F., Zou, J., Lin, H., Ying, Y., Luo, Y., Zhan, Z., Liu, P., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14279 · Cited by 36
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
Bragagnoli, A. S. C., Araújo, R. L. C., Ferraz, M. W. S., dos Santos, L. V., Abdalla, K. C., Comar, F., Santos, F. A., de Oliveira, M. A., Carvalheira, J. B. C., Cárcano, F. M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01208-6 · Cited by 36
Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
Anselmino, L., Baglioni, M. V., Malizia, F., Laluce, N. C., Etichetti, C. B., Marignac, V. L. M., Rozados, V. R., Scharovsky, O. G., Girardini, J. E., Rico, M. J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87525-z · Cited by 35
Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis
Jin, P., Jiang, J., Zhou, L., Huang, Z., Qin, S., Chen, H., Peng, L., Zhang, Z., Li, B., Luo, M., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216082 · Cited by 36
Age and Comorbidity Considerations Related to Radiotherapy and Chemotherapy Administration
Rodrigues, G., & Sanatani, M. S. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2012.05.004 · Cited by 35
Vázquez‐Martín, A., Oliveras‐Ferraros, C., Barco, S. D., Martı́n-Castillo, B., & Menéndez, J. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5456 · Cited by 35
Metformin, a biological and synthetic overview
Hernández‐Velázquez, E. D., Betancourt, C. A., Alonso‐Castro, Á. J., Ortíz‐Alvarado, R., López, J. A., Carmen, V. M., & Solorio‐Alvarado, C. R. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129241 · Cited by 36
Diabetes mellitus and risk of breast cancer: a large-scale, prospective, population-based study
Xiong, F., Wang, J., Nierenberg, J. L., Blarigan, E. L. V., Kenfield, S. A., Chan, J. M., Schmajuk, G., Huang, C., & Graff, R. E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02345-4 · Cited by 34
Elmahboub, Y., Albash, R., William, M. M., Rayan, A. H., Hamed, N. O., Ousman, M. S., Raslan, N. A., & Mosallam, S. (2024) · Molecules · doi:10.3390/molecules29071614 · Cited by 34
Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology
Barrière, G., Tartary, M., & Rigaud, M. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313020018 · Cited by 35
“Jiralerspong et al [29] Metformin and pathologic complete responses in breast cancer”
InfluentialCancer cachexia and diabetes: similarities in metabolic alterations and possible treatment,
Chevalier, S., & Farsijani, S. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2013-0369 · Cited by 36
“In a retrospective study of 2529 diabetic patients with breast cancer receiving chemotherapy, metformin use was associated with greater pathologic complete response, a powerful predictor of long-term survival, comparedwith diabetic patients not receivingmetformin (Jiralerspong et al. 2009).”
BackgroundDang, J., Jin, Z., Liu, X., Hu, D. X., Wang, J., Luo, Y., & Li, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7176 · Cited by 34
“In addition, previous studies have demonstrated that metformin could improve the survival of diabetic patients and decrease their incidence of cancer (8).”
Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents
Chen, Y., Zhao, N., Li, D., Zou, G., & Chen, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10564 · Cited by 34
“Metformin has been reported to enhance the antiproliferative effects of paclitaxel and cisplatin in breast cancer, lung cancer and other cells (24-27).”
BackgroundMetformin potentiates the anticancer effects of cisplatin under normoxic conditions in vitro
UEHARA, T., Mitsuhashi, A., Tsuruoka, N., & Shozu, M. (2014) · Oncology Reports · doi:10.3892/or.2014.3611 · Cited by 36
Esteva, F. J., Moulder, S., Gonzalez-Angulo, A. M., Ensor, J., Murray, J. L., Green, M. C., Koenig, K. B., Lee, M., Hortobágyi, G. N., & Yeung, S. J. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1977-9 · Cited by 34
“In one study of diabetic patients with early-stage breast cancer, those who received neoadjuvant chemotherapy with concomitant metformin had a higher rate of pathologic complete response than did those who received chemotherapy without metformin [20].”
Self-citationToi, M., Ohashi, Y., Seow, A., Moriya, T., Tse, G. M.-K., Sasano, H., Park, B., Chow, L. W., Laudico, A. V., Yip, C. H., et al. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq122 · Cited by 35
“Metformin, a drug that is administered to control diabetes, was reported to result in a higher pathologic complete response rate to neoadjuvant chemotherapy compared with a non-metformin group and a non-diabetic group (8).”
BackgroundMATE2 Expression Is Associated With Cancer Cell Response to Metformin
Chowdhury, S., Yung, E., Pintilie, M., Muaddi, H., Chaib, S., Yeung, M., Fusciello, M., Sykes, J., Pitcher, B., Hagenkort, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165214 · Cited by 33
Brownfoot, F., & Rolnik, D. L. (2024) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2024.102481 · Cited by 43
Metformin: a new option in cancer treatment
Belda-Iniesta, C., Pernía, O., & Simó, R. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0669-y · Cited by 33
“Patients that were treated with both metformin and chemotherapy had a higher pathological response rate compared with non-diabetic patients as well as with those diabetics that were not taking metformin [ 51 ].”
ResultJúnior, A. D. D. C., Pericole, F. V., & Carvalheira, J. B. C. (2018) · Clinics · doi:10.6061/clinics/2018/e412s · Cited by 32
“Since then, various studies in DM2 patients have shown that metformin use is associated with a reduced risk of several cancers (2,11,74-79), including prostate cancer (80,81), lung cancer (45,82,83), head and neck cancer (HNC) (84,85), breast cancer (86-88), pancreatic cancer (89), CRC (90-92), endometrial cancer (93)…”
BackgroundJacobi, O., Landman, Y., Reinhorn, D. J., Icht, O., Sternschuss, M., Rotem, O., Finkel, I., Allen, A. M., Dudnik, E., Goldstein, D. A., et al. (2021) · Oncology · doi:10.1159/000516671 · Cited by 34
Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Bo, S., Benso, A. S., Durazzo, M., & Ghigo, E. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345423 · Cited by 33
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again
Saxena, A., Becker, D. J., Preeshagul, I. R., Lee, K. S., Katz, E., & Levy, B. P. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0064 · Cited by 34
Bardella, C., Olivero, M., Lorenzato, A., Geuna, M., Adam, J., O'Flaherty, L., Rustin, P., Tomlinson, I., Pollard, P. J., & Di Renzo, M. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06160-11 · Cited by 33
“Preclinical (20, 21) and epidemiological (24, 31, 32) studies have prompted clinical trials (12, 15) to evaluate the effects of metformin on the treatment or prevention of human cancer.”
BackgroundMetformin and epithelial ovarian cancer therapeutics
Patel, S. V., Kumar, L., & Singh, N. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0235-7 · Cited by 32
Xiao, Y.-T., Zhang, S., Hou, G., Zhang, X., Hao, X., & Zhang, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1270-5 · Cited by 32
“Breast cancer patients (early stage) with diabetes who took metformin during neoadjuvant chemotherapy had a higher PCR rate than did patients taking other hypoglycemic drugs [7].”
ResultNeoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
van de Wiel, M., Dockx, Y., WYNGAERT, T. V. D., Stroobants, S. G., Tjalma, W. A. A., & Huizing, M. T. (2016) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2016.12.014 · Cited by 32
Nanoparticles Induce Autophagy via mTOR Pathway Inhibition and Reactive Oxygen Species Generation
Lu, J. Q., Hao, S.-L., & Yang, W. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0387 · Cited by 34
BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment
Andrieu, G. P., Shafran, J. S., Deeney, J. T., Bharadwaj, K. R., Rangarajan, A., & Denis, G. V. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0917-380rr · Cited by 33
Zhang, X., Jiang, Q., Su, Y., Bu, L., Sun, Z., Wu, X., Gao, B. X., Wang, L., Lin, Y., Xie, W., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02127-4 · Cited by 32
“As a result, diabetic patients who have received metformin administration, display a relatively lower risk of breast cancer incidence possibly due to the activation of AMPK [20].”
BackgroundCancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers
Kim, S. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.013 · Cited by 31
“Sao Jiralerspong reported that diabetic patients with breast cancer who were treated with metformin (antidiabetic drug) and neoadjuvant chemotherapy had a higher pathologic complete response rate than did similar patients not treated with metformin (Jiralerspong et al., 2009).”
InfluentialYang, X., Sun, D., Tian, Y., Ling, S., & Wang, L. (2014) · Tumor Biology · doi:10.1007/s13277-014-2926-5 · Cited by 31
“Moreover, recent evidence has indicated that metformin provides a synergistic effect when used in combination with other chemotherapies or radiotherapy against various cancers in several clinical cohort studies and may sensitize HCC to radiation-induced apoptosis [20, 21].”
BackgroundCombined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Chen, S., Zhu, X., Lai, X., Xiao, T. L., Wen, A., & Zhang, J. (2014) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557514666140820104444 · Cited by 31
“chemotherapy had a higher pCR rate than diabetics not receiving metformin in vivo [18]”
BackgroundInfluentialAlan, Ö., Telli, T. A., Aktaş, B., Koca, S., Ökten, I. N., HASANOV, R., Başoğlu, T., Arıkan, R., Demircan, N. C., Erçelep, Ö., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-02019-y · Cited by 31
Inhibition of tumor energy pathways for targeted esophagus cancer therapy
Shafaee, A., Dastyar, D. Z., Islamian, J. P., & Hatamian, M. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.005 · Cited by 32
“Importantly, diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy were found to have a higher pathologic complete response rate than diabetics not receiving metformin [60].”
BackgroundJang, E. K., Kim, W. G., Kwon, H., Choi, Y. M., Jeon, M. J., Kim, T. Y., Shong, Y. K., Kim, W. B., & Kim, E. Y. (2015) · European Thyroid Journal · doi:10.1159/000437365 · Cited by 31
Chemoprevention for breast cancer
Božović‐Spasojević, I., de Azambuja, E., McCaskill‐Stevens, W., Dinh, P., & Cardoso, F. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.005 · Cited by 32
“The rationale to test metformin as a new strategy in chemoprevention or in the adjuvant setting was further strengthen by retrospective clinical data showing higher rates of pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with BC who were being treated with metformin for diabetes.(66) Amo…”
Costa, D., Gigoni, A., Würth, R., Cancedda, R., Florio, T., & Pagano, A. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-59 · Cited by 32
“patients [7].”
Hypoxia and Metastasis in Breast Cancer
Rundqvist, H., & Johnson, R. S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_77 · Cited by 33
Metformin, B12, and Enhanced Breast Cancer Response to Chemotherapy
Garcia, A., & Tisman, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7857 · Cited by 31
Griffiths, R. I., Danese, M. D., Gleeson, M. L., & Valderas, J. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-613 · Cited by 30
“Preclinical data show an in vitro effect of metformin in breast cancer cells [2,30], and in an observational study in humans, metformin was associated with a higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy [31].”
BackgroundXue, L., Chen, F., Yue, F., Camacho, L., Kothapalli, S., Wei, G., Huang, S., Mo, Q., Ma, F., Li, Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05927-5 · Cited by 33
Self-citationSun, X., Zhang, P., Li, H.-H., Jiang, Z., Jiang, C., & Liu, H. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.9.4019 · Cited by 30
“In fact, some studies have found that metformin combined with chemotherapy drugs may enhance the effectiveness of chemotherapy (Jiralerspong et al., 2009).”
BackgroundDenkert, C. (2011) · Oncology Reports · doi:10.3892/or.2011.1162 · Cited by 30
“Recently, this has been investigated in a retrospective study where diabetic patients with breast cancer treated with metformin and neoadjuvant chemotherapy had a higher response rate than diabetics not receiving metformin (28).”
McCarty, M. F. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.10.041 · Cited by 29
Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?
Ganz, P. A., & Cole, S. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8820 · Cited by 30
Basic Assessment of the Older Cancer Patient
Extermann, M. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0161-5 · Cited by 29
“In one study, whereas diabetic patients had higher relapse rates from their breast cancer than normal controls, those treated with metformin actually had the lowest relapse rate of any group [ 59 ].”
ResultLai, H., Tsai, I., Chen, P., Muo, C., Chou, J., Peng, C.-Y., Lai, S., Sung, F., Lyu, S.-Y., & Morisky, D. E. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0674-0 · Cited by 29
AMPK activation—protean potential for boosting healthspan
McCarty, M. F. (2013) · AGE · doi:10.1007/s11357-013-9595-y · Cited by 30
Geraldine, N., Marc, A., Truyers, C., Mathieu, C., Stefaan, B., Wami, W. M., & Buntinx, F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.002 · Cited by 29
“[12] Jiralerspong S, Palla SL, Giordano SH, MericBernstam F, Liedtke C, Barnett CM, et al.”
BackgroundMetformin: A candidate for the treatment of gynecological tumors based on drug repositioning
Irie, H., Banno, K., Yanokura, M., Iida, M., Adachi, M., Nakamura, K., Umene, K., Nogami, Y., Masuda, K., Kobayashi, Y., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4075 · Cited by 32
“Of the 155 diabetic patients included in the study, 68 received metformin and 87 did not, along with anthracycline‐based chemotherapy regimens (49).”
BackgroundLee, K.-M., Lee, M., Lee, J., Kim, S. W., Moon, H., Noh, D., & Han, W. (2016) · Oncotarget · doi:10.18632/oncotarget.9522 · Cited by 29
“Furthermore, a retrospective study found that the addition of metformin to neoadjuvant chemotherapy yielded a significantly higher rate of pathologic complete response (pCR) in diabetic patients with breast cancer [4].”
BackgroundGanitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Yee, D., Isaacs, C. J., Wolf, D. M., Yau, C. S. F., Haluska, P., Giridhar, K. V., Forero, A., Chien, A. J., Wallace, A. M., Pusztai, L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00337-2 · Cited by 28
Can Natural Products Targeting EMT Serve as the Future Anticancer Therapeutics?
Anwar, S., Malik, J. A., Ahmed, S., Kameshwar, V. A., Alanazi, J., Alamri, A., & Ahemad, N. (2022) · Molecules · doi:10.3390/molecules27227668 · Cited by 30
Sehdev, A., & O’Neil, B. H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0359-z · Cited by 28
Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups
Cavalla, D., & Singal, C. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.019 · Cited by 29
Thigpen, J. T. (2010) · Yearbook of Oncology · doi:10.1016/s1040-1741(10)79494-x · Cited by 29
Insulinemia and the risk of breast cancer and its relapse
Formica, V., Tesauro, M., Cardillo, C., & Roselli, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01614.x · Cited by 29
McCarty, M. F. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.07.004 · Cited by 27
“for breast cancer, concurrent metformin therapy is associated with a higher rate of pathologic complete response [60].”
BackgroundTeoh, S. L., & Das, S. (2016) · Tumor Biology · doi:10.1007/s13277-016-5357-7 · Cited by 29
Meyerhardt, J. A., Irwin, M. L., Jones, L. W., Zhang, S., Campbell, N., Brown, J. C., Pollak, M., Sorrentino, A., Cartmel, B., Harrigan, M., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz096 · Cited by 30
“Observational studies have demonstrated that diabetics who take metformin are at lower risk than diabetics who take other agents of developing breast and colorectal cancer (33–35), and diabetics who take metformin after diagnosis may have improved response to chemotherapy (36) and lower cancer-related mortality (37–41…”
BackgroundDrug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials
Ioakeim‐Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza‐Pascual‐Salcedo, M., Miguel, A. G., Orlando, V., González‐Rubio, F., Fanlo, A., AZA, C. L., Ostasz, E., et al. (2023) · Cancers · doi:10.3390/cancers15112972 · Cited by 31
Evaluation of antagonistic effects of metformin with Cisplatin in gastric cancer cells.
Lesan, V., Ghaffari, S. H., Salaramoli, J., Heidari, M., Rostami, M., Alimoghaddam, K., & Ghavamzadeh, A. (2014) · Europe PMC (PubMed Central) · Cited by 28
The female breast and diabetes
Gouveri, E., Παπάνας, Ν., & Maltezos, E. S. (2011) · The Breast · doi:10.1016/j.breast.2011.02.019 · Cited by 28
Nienhuis, H. H., Gaykema, S. B. M., Timmer‐Bosscha, H., Jalving, M., Brouwers, A. H., Hooge, M. N. L., van der Vegt, B., Overmoyer, B. A., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.004 · Cited by 29
Zheng, Y., Zhu, J., Zhang, H., Liu, Y., & Sun, H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03963-7 · Cited by 28
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28
Lee, K. N., Torres, M. A., Troeschel, A. N., He, J., Gogineni, K., & McCullough, L. E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232581 · Cited by 27
Lu, Y., Xin, D., Guan, L., Xu, M., Yang, Y., Chen, Y., Yang, Y., Wang‐Gillam, A., Wang, L., Zong, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762523 · Cited by 27
“Patients with diabetes with breast cancer receiving metformin and neoadjuvant chemotherapy were shown to have a higher pathologic complete response rate than those who did not receive metformin (23).”
BackgroundMetformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis
Grossmann, M. E., Yang, D.-Q., Guo, Z., Potter, D. A., & Cleary, M. P. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0032-z · Cited by 28
Bostrom, B., Uppal, P. A., Chu, J., Messinger, Y. H., Gandrud, L. M., & McEvoy, R. C. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31829cdeba · Cited by 27
Ge, R., Wang, Z., Wu, S., Zhuo, Y., Otsetov, A., Cai, C., Zhong, W., Wu, C., & Olumi, A. F. (2015) · Oncotarget · doi:10.18632/oncotarget.5023 · Cited by 30
“Interestingly, many recent epidemiological studies have shown that metformin, a biguanide hypoglycemic, not only lowers the glucose level, but also significantly reduces cancer incidence and improves cancer patients’ survival, including prostate cancer in diabetic men [3–5].”
Lee, Y., Doonan, B. B., WU, J. M., & Hsieh, T. (2016) · Oncology Reports · doi:10.3892/or.2016.4740 · Cited by 26
“In tumorigenic settings, ample evidence has been obtained that exposure to metformin shows efficacy in patients diagnosed with malignant diseases including pancreatic (57) and breast cancer (58), and colorectal polyps (59).”
BackgroundRocca, A., Cortesi, P., Cortesi, L., Gianni, L., Matteucci, F., Fantini, L., Maestri, A., Giunchi, D. C., Cavanna, L., Ciani, R., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920985632 · Cited by 23
Defining the Molecular Nexus of Cancer, Type 2 Diabetes and Cardiovascular Disease
Cabarcas‐Petroski, S., Hurt, E., & Farrar, W. L. (2010) · Current Molecular Medicine · doi:10.2174/156652410793384187 · Cited by 28
New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (Review)
Umene, K., Banno, K., Kisu, I., Yanokura, M., Nogami, Y., Tsuji, K., Masuda, K., Ueki, A., Kobayashi, Y., Yamagami, W., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2221 · Cited by 26
Calip, G. S., Yu, O., Elmore, J. G., & Boudreau, D. M. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0744-3 · Cited by 26
Negative regulation of TGF-β by AMPK and implications in the treatment of associated disorders
Gao, J., Ye, J., Ying, Y., Lin, H., & Luo, Z. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy028 · Cited by 28
Assatse, Y. T., Ejuh, G. W., Tchoffo, F., & Ndjaka, J. M. B. (2019) · Chinese Journal of Physics · doi:10.1016/j.cjph.2019.01.014 · Cited by 26
Cai, H., Everett, R. S., & Thakker, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14694 · Cited by 26
“…inhibits tumour cell proliferation (Hadad et al., 2011; Schuler et al., 2015) and improves pathological complete response in cancer patients (Jiralerspong et al., 2009), a consensus on the beneficial effects of metformin against breast cancer is lacking, as several clinical trials failed…”
BackgroundShi, Y., Ma, Z., Cheng, Q., Wu, Y., Parris, A. B., Kong, L., & Yang, X. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118877 · Cited by 26
Almendáriz-Palacios, C., Mousseau, D. D., Eskiw, C. H., & Gillespie, Z. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239220 · Cited by 30
Tetsuo, F., Arioka, M., Miura, K., Inoue, T., Igawa, K., Tomooka, K., Takahashi‐Yanaga, F., & Sasaguri, T. (2021) · Oncogene · doi:10.1038/s41388-021-01958-4 · Cited by 25
“Particularly, mTOR and STAT3 have been attracting attention as therapeutic target molecules to improve TME, for instance, by reducing tumorassociated macrophages (TAMs) [57, 58], which have been shown to be significant constituents of breast cancer masses [59, 60].”
BackgroundDo we have enough data to confirm the link between antidiabetic drug use and cancer development?
Drzewoski, J., Drozdowska, A., & Śliwińska, A. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1029 · Cited by 25
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
Papanagnou, P., Stivarou, T., & Tsironi, M. (2016) · Pharmaceuticals · doi:10.3390/ph9020024 · Cited by 26
“A population-based study which recruited breast cancer women with or without DM treated with neoadjuvant chemotherapy demonstrated a significant increase in the rate of pathologic complete response (pCR) among the diabetics who received metformin and those who did not [139].”
BackgroundCuyàs, E., Buxó, M., Iglesias, M. J. F., Verdura, S., Pernas, S., Dorca, J., Álvarez, I., Torres‐Martínez, S., Pérez-García, J. M., Batista-López, N., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00193 · Cited by 25
“Second, diabetic patients with breast cancer receiving metformin during neoadjuvant chemotherapy were reported to benefit from a 3-fold greater pathological complete response (pCR) when compared with those who did not receive metformin (12).”
Metformin and survival in diabetic patients with breast cancer
El-Benhawy, S. A., & Elsheredy, H. (2014) · Journal of the Egyptian Public Health Association · doi:10.1097/01.epx.0000456620.00173.c0 · Cited by 25
Metformin As an Addition to Conventional Chemotherapy in Breast Cancer
Grenader, T., Goldberg, A., & Shavit, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4110 · Cited by 25
Drug Repurposing in the Development of Anticancer Agents
Ölgen, S., & Kotra, L. P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180713155702 · Cited by 26
Spierings, L. E. A. M. M., Lagarde, S. M., van Oijen, M. G. H., Gisbertz, S. S., Wilmink, J. W., Hulshof, M. C. C. M., Meijer, S. L., Anderegg, M. C. J., Henegouwen, M. I. V. B., & van Laarhoven, H. W. M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4850-3 · Cited by 24
Metformin's performance in in vitro and in vivo genetic toxicology studies
de Sant’Anna, J. R., Yajima, J. P. R. D. S., ROSADA, L. J., Franco, C. C. S., Prioli, A. J., Della-Rosa, V. A., Mathias, P. C. D. F., & de Castro‐Prado, M. A. A. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213480744 · Cited by 24
“The AMP-activated protein kinase (AMPK) pathway is a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in the cancer treatment.(2,8) The metformin potential anticancer effects have already been demonstrated in various mammalian cancer cells lines including panc…”
BackgroundObesity, Metabolic Syndrome, and Breast Cancer: From Prevention to Intervention
Li, Y. R., Ro, V., & Tchou, J. C. (2018) · Current Surgery Reports · doi:10.1007/s40137-018-0204-y · Cited by 24
“Additionally, recent studies have suggested a beneficial role for metformin in neoadjuvant therapy [54, 55].”
Ding, J., Gou, Q., Jin, J., Shi, J., Liu, Q., & Hou, Y. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172425 · Cited by 24
Keshandehghan, A., Nikkhah, S., Tahermansouri, H., Keshel, S. H., & Gardaneh, M. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1655073 · Cited by 24
“Early-stage BC patients who receive MTFN fully respond to neoadjuvant therapy (23).”
BackgroundThe Chemosensitizing Role of Metformin in Anti-Cancer Therapy
Tang, Z., Tang, N., Jiang, S., Bai, Y., Guan, C., Zhang, W., Fan, S., Huang, Y., Lin, H., & Ying, Y. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200918102642 · Cited by 24
McCune, K. R., Bhat‐Nakshatri, P., Thorat, M. A., Nephew, K. P., Badve, S., & Nakshatri, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1530 · Cited by 23
“Consistent with these observations, use of Metformin, a diabetic therapy, is associated with reduced cancer incidence, lower cancer-related mortality, and higher response to neoadjuvant therapy (48, 49).”
Result
Metadata
- Authors
- Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Breast Medical Oncology, Biochemistry and Molecular Biology, Quantitative Sciences, Surgical Oncology, Pharmacy, Molecular and Cellular Oncology, and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Gynecology and Obstetrics, University of Muenster, Muenster, Germany.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3297-3302
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2736070
- OpenAlex
- W2171998898
- Cited by
- 880
- References
- 42
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 34 · 2022: 31 · 2021: 51 · 2020: 43 · 2019: 60 · 2018: 34 · 2017: 42 · 2016: 54 · 2015: 53 · 2014: 73 · 2013: 97 · 2012: 76
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Breast Cancer Research Foundation
- Amgen
- American Society of Clinical Oncology
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k23ca121994-03)
- National Cancer Institute (1K23CA121994-01), K23-CA121994, 1K23CA121994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- metformin, breast cancer, diabetes mellitus, neoadjuvant chemotherapy, pathological complete response, predictors of treatment response
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Remission Induction, Multivariate Analysis, Logistic Models, Survival Analysis, Treatment Outcome, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
